Acadia Pharmaceuticals (ACAD) Gains from Investment Securities (2010 - 2026)

Acadia Pharmaceuticals' Gains from Investment Securities history runs 16 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 3.56% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (down 3.56% YoY), while the FY2025 annual figure was $4.2 million, down 76.27% from the prior year.
• Gains from Investment Securities was $9.1 million for Q1 2026 at Acadia Pharmaceuticals, up from $4.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $17.5 million in Q4 2024 to a low of $181252.0 in Q3 2025.
• Historically, Gains from Investment Securities has averaged $7.3 million across 5 years, with a median of $6.6 million in 2025.
• Biggest YoY gain for Gains from Investment Securities was 2207.94% in 2025; the steepest drop was 89.96% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $16.3 million in 2022, then grew by 1.75% to $16.6 million in 2023, then rose by 5.37% to $17.5 million in 2024, then plunged by 76.27% to $4.2 million in 2025, then surged by 118.63% to $9.1 million in 2026.
• The last three Gains from Investment Securities figures came in at $9.1 million (Q1 2026), $4.2 million (Q4 2025), and $181252.0 (Q3 2025), per Business Quant data.